|
|
Volumn 103, Issue 17, 2011, Pages 1284-1285
|
|
Ovarian cancer treatments on the horizon
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
BRCA1 PROTEIN;
BRCA2 PROTEIN;
CARBOPLATIN;
DOXORUBICIN;
GEMCITABINE;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;
OLAPARIB;
PACLITAXEL;
PLATINUM DERIVATIVE;
VASCULOTROPIN;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RELAPSE;
CLINICAL PROTOCOL;
COLON CANCER;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG TARGETING;
FROZEN SECTION;
GENE MUTATION;
HISTOPATHOLOGY;
HUMAN;
MAINTENANCE THERAPY;
MONOTHERAPY;
NOTE;
OVARY CANCER;
OVERALL SURVIVAL;
PATIENT SELECTION;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RISK BENEFIT ANALYSIS;
TUMOR VASCULARIZATION;
ADENOCARCINOMA, CLEAR CELL;
ADENOCARCINOMA, MUCINOUS;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHRONIC DISEASE;
CLINICAL TRIALS AS TOPIC;
CYSTADENOCARCINOMA, SEROUS;
DRUG APPROVAL;
FEMALE;
HUMANS;
MOLECULAR TARGETED THERAPY;
OUTCOME ASSESSMENT (HEALTH CARE);
OVARIAN NEOPLASMS;
PHTHALAZINES;
PIPERAZINES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 80052664716
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr343 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
